Paris Roach
Eli Lilly and Company
15 Papers
160 Citations
Paris Roach is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Insulin lispro & Type 2 diabetes. The author has an hindex of 6, co-authored 12 publications. Previous affiliations of Paris Roach include Indiana University.
Chat about Author
Papers
Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin
Tim Heise,Christian Weyer,Andreas Serwas,Sebastian Heinrichs,Johannes Osinga,Paris Roach,Jim Woodworth,Uwe Gudat,Lutz Heinemann +8 more
TL;DR: This study shows that the pharmacodynamic and pharmacokinetic properties of insulin lispro are preserved in stable mixtures with NPL insulin.
118
Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50
TL;DR: Compared with human insulin mixtures, twice-daily administration of insulin lispro mixtures resulted in improved postprandial glycemic control, similar overall glycemic Control, and less nocturnal hypoglycemia, as well as offering the convenience of dosing closer to meals.
81
Nighttime Insulin Kinetics and Glycemic Control in Type 1 Diabetes Patients Following Administration of an Intermediate-Acting Lispro Preparation
Maureen M. J. Janssen,Sandrina Casteleijn,Walter Devillé,Corrie Popp-Snijders,Paris Roach,Robert J. Heine +5 more
TL;DR: NPH and NPL are equally effective in controlling overnight glycemia, and no differences were detected in the total area under the curve (AUC) for insulin, in insulin levels before breakfast, or in glucose levels before Breakfast.
26
Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide.
TL;DR: Compared with maximum-dose GB, twice-daily injections of Mix25 resulted in improved glycemic control and treatment satisfaction, and were associated with a predictably higher rate of hypoglycemia in this group of patients with type 2 diabetes who were inadequately controlled withmaximum-doseGB.
25
Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.
Paris Roach,Paris Roach,Shan Bai,Bernard Charbonnel,Agostino Consoli,Claudio Taboga,Antonio Tiengo,Geremia B. Bolli +7 more
TL;DR: This study assessed mean late postprandial glycemic control during treatment with a premixed formulation consisting of a high proportion of LP (75% LP/25% NPL; H) and a medium proportion ofLP (50% LP-based intermediate-acting insulin; M) in patients with type 1 diabetes mellitus (DM, conducted at 4 centers in Italy and 1 center in France.
13